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Abstract
Background: Ewing’s sarcoma (ES) and desmoplastic small round cell tumors (DSRCT) are small round blue cell tumors
driven by an N-terminal containing EWS translocation. Very few somatic mutations have been reported in ES, and none have
been identified in DSRCT. The aim of this study is to explore potential actionable mutations in ES and DSRCT.
Methodology: Twenty eight patients with ES or DSRCT had tumor tissue available that could be analyzed by one of the
following methods: 1) Next-generation exome sequencing platform; 2) Multiplex PCR/Mass Spectroscopy; 3) Polymerase
chain reaction (PCR)-based single- gene mutation screening; 4) Sanger sequencing; 5) Morphoproteomics.
Principal Findings: Novel somatic mutations were identified in four out of 18 patients with advanced ES and two of 10
patients with advanced DSRCT (six out of 28 (21.4%));KRAS (n = 1), PTPRD (n = 1), GRB10 (n = 2), MET (n = 2) and PIK3CA (n = 1).
One patient with both PTPRD and GRB10 mutations and one with a GRB10 mutation achieved a complete remission (CR) on
an Insulin like growth factor 1 receptor (IGF1R) inhibitor based treatment. One patient, who achieved a partial remission (PR)
with IGF1R inhibitor treatment, but later developed resistance, demonstrated a KRAS mutation in the post-treatment
resistant tumor, but not in the pre-treatment tumor suggesting that the RAF/RAS/MEK pathway was activated with
progression.
Conclusions: We have reported several different mutations in advanced ES and DSRCT that have direct implications for
molecularly-directed targeted therapy. Our technology agnostic approach provides an initial mutational roadmap used in
the path towards individualized combination therapy.
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Introduction
Ewing’s sarcoma (ES) and desmoplastic small round cell tumor
(DSRCT) are small cell sarcomas characterized by the transloca-
tion of chromosome 22 to chromosome 11, resulting in fusion of
the EWSR1 gene to the FLI1 gene (and several rarer fusion
partners) [1,2] in the case of ES (EWSR1-FLI1), and to the WT1
gene in the case of DSRCT (EWSR1-WT1) [3,4,5]. While both
are mediated by the EWS translocated chimera, the clinical
presentation, pathologic features, and response to therapy are
different. They have been treated with similar chemotherapy
regimens using a multi-disciplinary approach but this does not
reflect similar biology. Although genotypically and phenotypically
different, historically they have been grouped together based on
their shared sensitivity to chemotherapies otherwise used for
Ewing’s sarcoma. For Ewing’s sarcoma, in the United States, the
current cytotoxic chemotherapy-based standard of care promoted
by the Children’s Oncology Group has resulted in steadily
improved survival rates over the last four decades for the 60%
of ES patients fortunate enough to present with radiographically
localized disease [6]. Twenty-three percent of patients present with
metastatic disease at diagnosis. Unfortunately, despite equivalent
response rates among those who present with metastatic disease,
the antineoplastic responses are often short-lived and the 5-year
survival of this patient population remains stubbornly in the 30%
range [1,7]. Early phase studies have demonstrated remarkable
responses in patients with advanced ES treated with an insulin-like
growth factor-1 receptor (IGF1R) antibody, with or without an
mTOR inhibitor, albeit in only a small subset (10–14%) of
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individuals [1,8,9,10,11,12,13]. To date, no predictive biomarkers
of IGF-1R response have been identified and only recently have
resistance mechanisms, such as shift from the IGF-1R/IGF-1 axis
towards IR-A/IGF-2, been identified [11,14]. For patients with
DSRCT, the chemotherapy, radiotherapy, and surgical approach-
es have not been standardized, given the extreme rarity of the
disease. [15,16,17]. The most commonly used cytotoxic regimens
employ alkylator and anthracycline chemotherapy similar to those
administered in Ewing’s sarcoma.
Recent identification of molecular mutations such as BRAF
V600E in some melanomas as well as ALK rearrangements in
non-small cell lung cancer has enabled targeted therapies directed
toward such anomalies and significantly altered the therapeutic
landscape for afflicted patients [18,19]. While EWSR1-FLI1 and
EWSR1-WT1 translocations occur in virtually all ES and DSRCT
patients, respectively, the resulting fusion proteins have not proved
to be druggable targets. Therefore, an alternative approach would
be to expand the therapeutic focus to ancillary genetic aberrations
infrequently encountered in those tumor types. Toward that end, a
recent study using sequence-based genotyping identified mutations
in 4% (three of 75 patients or cell lines with ES), including BRAF,
CTNNB1, and NRAS [20]. No somatic mutations have been
identified in patients (total = 24 samples) with DSRCT [20]. We
recently reported germline Protein tyrosine phosphatase delta
(PTPRD) mutations in a small pilot study in patients with Ewing’s
sarcoma [21].
Here we report potential actionable mutations identified in four
patients with advanced ES and in two patients with advanced
DSRCT. The mutations include KRAS (G13N), PTPRD
(W775D), GRB10 (Q107stop and V109A), MET (T1010I and
N375S) and PIK3CA (M1040I and G1049S). Correlations with
response and resistance to IGF1R inhibitor based regimen in these
patients are discussed.
Patients and Methods
We reviewed 62 consecutive patients with advanced metastatic
ES or DSRCT who were referred to the Department of
Investigational Cancer Therapeutics (A Phase 1 program) and/
or the Department of Pediatrics or Department of Sarcoma at The
University of Texas MD Anderson Cancer Center (MD
Anderson). Of the 62 patients, 28 patients had tumor archival
tissue available that could be analyzed by one of the following
methods: 1) next-generation sequencing using the Clinical
Laboratory Improvement Amendment (CLIA)-approved Founda-
tionOne platform (Foundation Medicine, Cambridge, MA; 182
genes tested); 2) CLIA-approved mutation screening by Multiplex
PCR/Mass Spectroscopy (Knight Cancer Institute, Oregon, Ohio;
53 genes tested); 3) CLIA-approved polymerase chain reaction
(PCR)-based single- gene mutation screening in the Department of
Pathology at MD Anderson (up to 10 genes tested); 4) next-
generation whole exome sequencing in the Center of Targeted
Therapy CORE at MD Anderson; 5) Sanger sequencing; 6)
immunohistochemical and morphoproteomic analyses of tumor
samples collected from patient # 1 were performed, as previously
described [11,22]. Briefly, for patient # 1, morphoproteomics and
immunohistochemical probes were used to detect p-ERK1/2
(Thr202/Tyr204) ([Cell Signaling Technology, Beverly, MA]
along with negative controls [11,22]. Testing was done according
to tissue availability, test and physicians’ choice. This study and all
treatments were approved by the MD Anderson Institutional
Review Board and conducted in accordance with the MD
Anderson Institutional Review Board requirements. The data
from this manuscript is based on CLIA certified next generation
sequencing from commercially available resources. As such we do
not have access to the primary data set. However, data can be
made available to researchers upon request. Because this is a
retrospective analysis the consent requirements were waived by the
MD Anderson Institutional Review Board and informed consents
were obtained from patients for collection of samples at the time of
screening or enrollment of patients to the clinical trials.
Results
Among the 28 patients tested for molecular aberrations, 18 had
ES and 10 had DSRCT. Four ES patients (22.2%) and two
DSRCT patients (20%) had secondary mutations, including
GRB10 (n = 2), PTPRD (n = 1), KRAS (n = 1), MET (n = 2) and
PIK3CA (n = 1) (Table 1). All patients had metastatic disease. The
medium age of the 28 patients at diagnosis was 22 years (range 9 to
52 years). Twenty were men and most had been heavily pretreated
with chemotherapy with a median of four prior systemic
treatments at the time of tissue acquisition (range, 0 to11). The
prior therapies consisted of standard front-line alkylator and
anthracycline-based chemotherapy as is standard in the USA and
Europe: vincristine, adriamycin, cyclophosphamide, ifosfamide
and etoposide. In addition, several patients were treated with
additional standard second-line and third -line agents like
temozolomide/irinotecan, topotecan/cyclophosphamide and
gemcitabine/docetaxel.
Of interest, both of the patients with GRB10 mutations (cases
#2 and #3, Table 1) responded to therapy with an IGF1R plus
mTOR inhibitor and both achieved a complete remission (CR)
[10]. One of the patients (case #2) also attained a prior CR with
IGF1R inhibitor alone [8,11,13] (Figure 1). Case # 2 had been
selected for an in-depth molecular analyses with the use of next
generation exome sequencing and Foundation One (Foundation
Medicine) 182 gene panel interrogation because of her excellent
response (CR) after IGF1R inhibitor therapy. Because of the
finding of GRB10 mutation in case #2, mutational analysis of
GRB10 was also performed on tumor from case #3 (who also
achieved a CR after IGF1R inhibitor therapy) and, remarkably,
was also positive by Sanger sequencing.
The Grb10 protein sends a negative feedback signal to IGF1R,
hence inhibiting the IGF1R signal; a loss of function GRB10
mutation may therefore be expected to be associated with
activated IGF1-R signaling (Figure 2) [23,24]. Case # 2 also
demonstrated a protein tyrosine phosphatase receptor type D
(PTPRD) mutation that would truncate this protein (Table 1). The
PTPRD protein dephosphorylates STAT3, whereas IGF1R is
important in STAT3 phosphorylation [21,25]. A PTPRD
mutation would be expected to inhibit STAT3 dephosphorylation,
resulting in accumulated phosphorylated STAT3 (Figure 2).
Because of the role of IGF1R in enabling STAT3 phosphoryla-
tion, inhibiting IGF1R might diminish the up regulation of
STAT3 phosphorylation effected by mutated PTPRD. Of interest,
increased expression of phospho-STAT3 has been implicated in
ES pathogenesis [26].
One patient (Case # 1, Table #1) received IGF1R/mTOR
inhibitor therapy and achieved a partial remission (PR) for 6
months, but developed resistance to the therapy. A KRAS
mutation was identified in the resistant tumor, but not in the
pre-treatment tumor. This was c.37_38GG.AA and was reported
in the 53 gene sequenom panel (Knight Diagnostics assay). In
addition, immunohistochemistry-based morphoproteomics in the
tumor specimen showed that the ras/Raf kinase/extracellular
signal-regulated kinase (ERK) pathway was constitutively activated
with chromogenic signal observed, up to 3+ in nucleus and 6 in
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the cytoplasm, for p-ERK 1/2 (Thr 202/Tyr 204) (Figure 3). A
fourth patient (Table 1, Case # 4), whose tumor demonstrated a
MET mutation did not receive IGF1R inhibitor therapy. The
mutation was detected in codon 1010 (ACT to ATT) of the MET
gene that would change the encoding amino acid from Thr to Ile
(p.T1010I) using a screening assay (PCR-based primer extension
analysis).
Of the ten DSRCT patients tested, one patient had a MET
mutation. Mutation was detected in codon 375 (AAC to AGC) of
the MET gene that would change the encoding amino acid from
Asn to Ser (N375S). The other had two mutations in the PIK3CA
gene (Table # 1, Case #19 and # 20). Mutation was detected in
codon 1040 (ATG to ATA) in exon 20 of the PIK3CA gene that
would change the encoding amino acid from Met to Ile (M1040I).
A second mutation detected in codon 1049 (GGT to AGT) of the
PIK3CA gene that would change the encoding amino acid from
Gly to Ser (G1049S).
Discussion
Our study shows that 21.4% of patients (6 of 28) with advanced,
heavily pretreated Ewing’s sarcoma family of tumors (ES, n= 18;
DSRCT, n=10) had secondary somatic molecular aberrations,
including mutations in KRAS, PTPRD, GRB10, MET and
PIK3CA. Interestingly, we recently reported germline PTPRD
mutations in three out of eight (37.5%) patients with metastatic
Ewing’s sarcoma [21]. Previous studies by Shukla et al [17]
reported molecular aberrations in 3 of 75 patients with ES (4%)
and 0 of 24 patients with DSRCT [20]. The higher incidence of
somatic mutations in our current study may be due to evolution of
technologies. Shukla et al [17] had used a 29 gene panel sequenom
assay while we used a range of evolving technologies, including
next generation exome sequencing, a 53-gene panel sequenom
(Knight Diagnostics) and a 182 gene panel (Foundation One next
generation panel) in selected patients. In addition, our patients all
had advanced disease with multiple prior therapies. While the
number and type of prior therapies could have an effect on the
Table 1. Ewing’s sarcoma and Desmoplastic small round cell tumor (DSRCT) patients whose tumors were analyzed for somatic
aberrations.
Pt# Diagnosis Mutation Methods used for molecular analysis
1 Ewing’s KRAS: G13N Knight Diagnostics 53 gene panel (Sequenome) Foundation One
182 gene panel (Foundation Medicine), MDACC single gene PCR
based assay
2 Ewing’s PTPRD:W775stop GRB10:Q107stop Foundation One 182 gene panel (Foundation Medicine), Next
generation sequencing
3 Ewing’s GRB10: V109A Sanger sequencing
4 Ewing’s MET: T1010I MDACC single gene PCR based assay
5 Ewing’s none ‘’
6 Ewing’s none ‘’
7 Ewing’s none ‘’
8 Ewing’s none ‘’
9 Ewing’s none ‘’
10 Ewing’s none ‘’
11 Ewing’s none ‘’
12 Ewing’s none ‘’
13 Ewing’s none ‘’
14 Ewing’s none ‘’
15 Ewing’s none ‘’
16 Ewing’s none ‘’
17 Ewing’s none Foundation One 182 gene panel (Foundation Medicine), Next
generation sequencing
18 Ewing’s none MDACC single gene PCR based assay
19 DSRCT MET:N375S ‘’
20 DSRCT PIK3CA:M1040I&G1049S ‘’
21 DSRCT none ‘’
22 DSRCT none ‘’
23 DSRCT none ‘’
24 DSRCT none ‘’
25 DSRCT none ‘’
26 DSRCT none ‘’
27 DSRCT none ‘’
28 DSRCT none ‘’
doi:10.1371/journal.pone.0093676.t001
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evolution of type and pattern of mutation, our study did not reveal
a pattern, though a larger group may be needed for a robust
analysis of specific associations. Shukla et al. [17] found BRAF,
NRAS and CTNNB1 mutations in their ES patients and cell lines,
while we found KRAS, PTPRD,GRB10 and MET. Together,
these results suggest that advanced and resistant ES (and DSRCT)
may be driven by diverse secondary aberrations.
The specific genetic aberrations and their correlation with
response and resistance may be also illuminating. For instance,
patient 1 (Table 2) achieved a PR on combined IGF1R and
mTOR inhibitor therapy lasting six months. In that patient, tissue
was available (both pre- and post-treatment tumors) and only the
post-treatment tumor showed a KRAS mutation. This result
suggests an adaptive mechanism of resistance to IGF1R/mTOR
attributable to the RAS/RAF/MEK pathway (Figure 2) and is
consistent with those shown previously by morphoproteomic
analysis where resistance to IGF1R/mTOR inhibitor was
associated with ERK activation [11]. An impact of the KRAS
mutation was confirmed in this patient’s tumor tissue by
immunohistochemistry-based morphoproteomics which demon-
strated that the Ras/Raf kinase/extracellular signal-regulated
kinase (ERK) pathway was constitutively activated with chromo-
genic signal observed, up to 3+ in nucleus and 6 in the cytoplasm,
for p-ERK 1/2 (Thr 202/Tyr 204) (Figure 3). Acquired KRAS
mutations have also been implicated as a mechanism of resistance
after anti-EGFR targeted therapy in colorectal cancer.
[27,28,29,30]. In addition, it has been shown that the emergence
of KRAS mutant clones can be detected months before
radiographic progression [27,29]. In colorectal cancer, it has been
suggested that early initiation of a MEK inhibitor may be a
rational strategy for delaying or reversing drug resistance [27,29].
While it was not possible to provide this particular patient with a
MEK inhibitor concurrently with combined IGF-1R/mTOR
inhibition, due to constraints inherent in clinical trials, joint
blockade of the MAPK and PI3K/Akt/mTOR cascades +/2
IGF-1R inhibition may be an interesting approach for patients
who acquire resistance to IGF-1R/mTOR-based therapies.
Patient 2 (ES) (Table 1) initially received IGF1R antibody
treatment and achieved a CR for nearly three years before
developing resistance [11]. After subsequent enrollment in a study
of combined IGF1R/mTOR inhibition, she achieved a second
CR that lasted two years. Two mutations were identified in her
tumor sample collected between the two lines of treatment, a
GRB10 Q107stop mutation and a PTPRD W775 stop mutation.
The latter mutation results in a truncated non-functional protein
product incapable of dephosphorylating STAT3 [25]. (Of interest,
STAT3 phosphorylation is found in about 50% of Ewing’s
sarcomas [22].) The loss of PTPRD function would be expected to
suppress STAT3 dephosphorylation and lead to accumulated
phosphorylated STAT3, especially under conditions of activated
p-IGF1R [26,31] (Figure 2). One could reasonably speculate that
patient 2 responded to IGF1R therapy, even in the presence of a
mutated PTPRD, because p-STAT3 remains critically dependent
on intact IGF-1R signaling for downstream effects.
As mentioned, patient 2 (Table 2) also had a GRB10 mutation.
The growth factor receptor-bound protein 10 (Grb10) is reported
to be an mTORC1 substrate that acts downstream of IGF1R
pathway [23,24]. The mTORC1 protein regulates the phosphor-
ylation of Grb10 at S501 and S503, which indirectly results in the
inhibition of PI3K, and thus regulates the IGF1R pathway
through a negative feedback [24] (Figure 2). Mutation of Q107 to
a stop codon, as found in this patient, would be expected to lead to
a truncated Grb10 protein and loss of the phosphorylation sites on
Grb10. This, in turn, would be expected to abrogate the negative
feedback regulation of Grb10 and result in enhanced IGF1R
pathway activity. Among a number of possible mechanisms of
acquired resistance, this mutation may therefore have contributed
to the eventual development of resistance to the IGF1R inhibitor
treatment.
Patient 3 (ES) (table 1) achieved a CR, which lasted for two
years in response to a combination regimen using an IGF1R and
an mTOR inhibitor. This patient was specifically studied for a
GRB10 mutation because of the similarity in his outcome to that
of patient #2. A GRB10 V109A mutation was identified in his
Figure 1. CT of the chest in Case# 2 with Ewing’s sarcoma response to single agent IGF1R antibody alone [11]. Left panel shows lung
metastases before IGF1R antibody therapy and right panel shows response to therapy after six weeks of treatment [11].
doi:10.1371/journal.pone.0093676.g001
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tumor tissue, which would not be expected to abrogate GRB10
function as the Q107 stop mutation previously noted in patient 2.
However, it is possible that the V109A mutation resulted in a
sufficient conformational change of the Grb10 protein to impair
the negative feedback to the IGF1R pathway.
In addition to the mutations in GRB10 and PTPRD that can
directly affect IGF-1R signaling, an unexpected mutation in MET
was identified in patients with ES and DSRCT. Patient 4 (ES,
Table 2) demonstrated a MET T1010I mutation, which has been
reported in lung cancer patients [32] but never in ES. MET
belongs to the receptor tyrosine kinase (RTK) family and has been
known to stimulate cancer cell growth [33]. The T1010I mutation
is located in the juxtamembrane domain, which is essential for
catalytic function of receptor tyrosine kinases [34]. The mutation
may compromise the negative feedback function of the MET
pathway, and thus lead to tumor growth. Patient 19 (DSRCT,
Table 2) also demonstrated a c-MET N375S mutation in his
tumor tissue. This is the most frequent mutation in MET and has
primarily been reported in patients with lung cancer. However,
this is the first time that the mutation has been reported in a
patient with DSRCT. The N375S mutation has been previously
observed as contributing to the resistance of MET to its inhibitors
[35].
Patient 20 (DSRCT, Table 2) demonstrated two PIK3CA
mutations, M1040I and G1049S, both located in the kinase
domain of p110a near the activation loop [36]. The protein
product expressed by PIK3CA is p110a, which forms a PI3K
complex with p85a [37]. The PI3K/AKT/mTOR pathway
regulates cell proliferation and tumor growth [38]. The M1040I
and G1049S mutations are located in the kinase domain of p110a,
Figure 2. Schematic figure of the IGF1R pathway, regulation of STAT3 phosphorylation and negative feedback of Grb10. IGF1R is
one of the regulators for STAT3 phosphorylation while PTPRD dephosphorylates STAT3. STAT3 is recruited to IGF1R for phosphorylation. IGF1R is
modulated by several downstream cascades, including PI3K, AKT and mTOR. mTOR phosphorylates Grb10, which in turn inhibits the IGF1R pathway.
doi:10.1371/journal.pone.0093676.g002
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near the activation loop [36]. H1047 mutations have been
reported to result in enhanced kinase activity [39], one may
hypothesize that M1040 and G1049 mutations located in the same
helix with H1047 would similarly bolster the kinase activity of
p110a by inducing an active conformation of the kinase activation
loop. Yet, the precise role of these mutations in ES or DSRCT as
well as the effectiveness of PI3K inhibitors remains to be validated.
There are several important limitations to this study. First, it is a
descriptive study. Indeed, the analysis was largely retrospective
with a variety of different methods used for molecular profiling.
Second, the patients selected for in-depth molecular assessment
were enriched for those who had responded to biologically-
targeted therapy. Third, there was a lack of matched normal
tissue, so it is unclear to what extent some of these aberrations
might be somatic versus germ-line. Fourth, there were limitations
in tissue availability and an evolution in the technologies used to
analyze molecular features. As a result, while our research
identified the emergence of a number of novel mutations in ES
and DSRCT, their frequency and association with response
requires additional study. Lastly, a series of controlled experiments
are needed to test and validate the functional impact of some of
these aberrations. Our findings should therefore be viewed as
hypothesis generating.
In summary, we have reported diverse secondary aberrations in
advanced ES and DSRCT. Some of these aberrations may be
actionable and, therefore, potentially have implications for
molecularly-directed targeted therapy. As the technology to assess
whole genomes, transcriptomes and more is evolving rapidly, it is
likely that these techniques will be increasingly applied, and may
reveal even more complex molecular portfolios for patients with
metastatic Ewing’s sarcoma and desmoplastic small round cell
tumor.
Figure 3. Immunohistochemistry based morphoproteomics of Ewing’s sarcoma sample that showed KRAS mutation post IGF1R
therapy (Patient 1). The Ras/Raf kinase/extracellular signal-regulated kinase (ERK) pathway was constitutively activated with chromogenic signal
observed, up to 3+ in nucleus and 6 in the cytoplasm, for p-ERK 1/2 (Thr 202/Tyr 204) (left hand panel) with the overnight negative control (Right
hand panel).
doi:10.1371/journal.pone.0093676.g003
Table 2. Characteristics of Ewing’s sarcoma and DSRCT patients with somatic mutations.
Patient* #
Age at
Dx Pathology/fusion type
Best Reponse
to IGF1R
inhibitor
Best Response
to IGF1R+mTOR
inhibitor Mutation Time of tumor sample
1 16 CD99+;EWSR1(22q12) N/A PR KRAS G13N (c.37_38GG.AA) Tumor resistant to IGF1R+
mTOR inhibitor (Pre-
treatment sample did not
show KRAS mutation)
2 24 CD99+;EWSR1(22q12) CR CR PTPRD W775stop GRB10
Q107stop
Tumor resistant to IGF1R
inhibitor
3 13 CD99+;EWSR1(22q12) N/A CR GRB10 V109A Before treatment with
IGF1R inhibitor
4 20 CD99+;EWSR1(22q12) N/A N/A MET T1010I
19 13 EWSR1-WT1 N/A N/A MET N375S
20 52 EWSR1-WT1 N/A N/A PIK3CA M1040I, G1049S
* Patient numbers according to Table 1.
Abbreviations: CR- Complete remission, PR- Partial remission,N/A-Not applicable.
doi:10.1371/journal.pone.0093676.t002
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